SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Regulatory & Safety

Read more breaking news

 

 
Dispatches from Informex

Updated IPEC Guide Steers Excipient Manufacturers Away From Unnecessary Tests

By Zachary Brennan , 21-Feb-2013
Last updated on 21-Feb-2013 at 10:07 GMT2013-02-21T10:07:30Z

IPEC Guide Steers Excipient Manufacturers Away From Unnecessary Tests
Loading...

Excipient firms that skip lot testing or use alternative analysis methods should justify their decisions according to a new COA guide issued by IPEC Americas. 

In-Pharmatechnologist.com sat down with Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients Auditing, Inc., and John Giannone, incoming IPEC-Americas chairman, to discuss the updated guide as well as other concerns for excipient manufacturers and the lack of GMP certifications from the US FDA.

It’s not clear in the USP that you’re not allowed to do skip lot testing,” Silverstein said, noting that the FDA’s GMP requirements call for either the supplier or customer to run the test. But the USP will not take issue with skipped tests if the manufacturers action still complies with the monograph requirements, Silverstein said.

Some of the tests also don’t provide any value in terms of patient safety, so under certain circumstances, the tests will not have to be conducted.

IPEC notes in the updated guide four instances in which alternatives to finished excipient testing “might be justified.” Such cases include:

  • An impurity, by-product or unreacted raw material could not be present in the product because the raw materials and chemical reactions used could not contain or generate it above the specified limits;
  • A stable process is indicated though a high Process Capability Index;
  • When in-process analyses show that the property which is determined at reduced frequency is stable and within specification and when repeating a test on each batch would be redundant; and
  • An analysis of a parameter on every batch in process has been shown to provide assurance that the final test requirement can be met and therefore the finished excipient can be tested at a reduced frequency.

These cases should not be considered all-inclusive or where alternatives are necessarily appropriate, IPEC warns, adding that for all testing, excipient suppliers should develop and maintain documentation outlining the process control systems and validation data justifying the use of alternatives.

Regardless of the skipped testing, IPEC wants pharmaceutical companies on an annual basis to confirm that the COAs are authentic and verified, Silverstein said. But this might be more difficult than expected because of the difficulty in ensuring the authenticity and signatures of all COAs issued by every excipient manufacturer that a pharma company uses.

There’s no requirement in the US government to produce” a GMP certification for excipient manufacturers, Giannone said.

And although the recently passed FDASIA legislation will require pharmaceutical companies to provide lists of the sources of all of their ingredients, the FDA does not have the capability or the expertise to conduct audits of excipient companies.

The FDA will have the option to conduct the audits,” Silverstein said.

Manufacturer, Supplier Sites

In addition, IPEC clarifies in the updated guide that the original manufacturer and manufacturing site must be identified if they are different from the supplier or supplier location so users can be assured that a manufacturing site has not changed without their knowledge. “It is essential that the manufacturer be known to the user,” IPEC notes. Codes to protect the confidentiality of the supply chain can be used in the COA, according to IPEC, as long as the user can identify both the manufacturer and its site.

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

Customers to Save up to 65% as ASI and Chromatan Pen Single-Use Deal

ASI has teamed up with Chromatan in order to deliver single-use and column-free capture...

Updated IPEC Guide Steers Excipient Manufacturers Away From Unnecessary Tests

John Giannone - incoming IPEC-Americas chairman

Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients...

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

ATMI: Single Use Bioreactors on the Up, but US Tails Europe

Special Report from ATMI's Belgian Facility

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

BASF nutrition president on high-end omega-3, Equateq and the phood “white space”

Walter Dissinger

President , BASF nutrition and health

Optimism is returning to the pharma fine chemicals sector, says analyst

Optimism is returning to the pharma fine chemicals sector, says analyst

Jan Ramakers

Industry consultant, Jan Ramakers Fine Chemical Consulting Group

Capsugel expands liquid fill capsule capabilities

Keith Hutchison,

Senior VP of research and development (R&D) , Capsugel

New filtration tech boosts biomanufacturing yields, says Sartorius

New filtration tech boosts biomanufacturing yields, says Sartorius

Jens Meyer

Product manager for filtration technologies, Sartorius Stedim

Submit good REMS proposals for FDA brownie points, says RAPS author

Submit good REMS proposals for FDA brownie points, says RAPS author

Ed Tabor

VP of strategic drug development , Quintiles

William Reed Business Media Holiday video

Happy Holidays 2014 from William Reed Business Media!

The holidays are fast upon us, so let’s put ‘business’ to one side and...

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Missy Lowery

Marketing Manager for the Americas, Capsugel

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Cory Stevenson & Brandon Pence

Thermo Fisher Scientific

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

ATMI: Single-Use Could Replace Multi-Use, as Potency Increases

Eric Isberg

Global Product Manager, ATMI

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Tech and Regulatory Issues? Biotech/Manufacturing Firms Discuss

Purification bottlenecks, integrating single-use technologies and low cost companies are just some of the...

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products